Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Role of favipiravir in the treatment of COVID-19
Shashank Joshi, Jalil Parkar, Abdul Samad Ansari, et al.
International Journal of Infectious Diseases (2020) Vol. 102, pp. 501-508
Open Access | Times Cited: 422

Showing 1-25 of 422 citing articles:

Temperature-Responsive Multilayer Films Based on Block Copolymer-Coated Silica Nanoparticles for Long-Term Release of Favipiravir
Li Xu, Xingxing Zhang, Zihan Chu, et al.
ACS Applied Nano Materials (2021) Vol. 4, Iss. 12, pp. 14014-14025
Closed Access | Times Cited: 145
Gastrointestinal manifestations in COVID-19
Jayani Kariyawasam, Umesh Jayarajah, Rishdha Riza, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene (2021) Vol. 115, Iss. 12, pp. 1362-1388
Open Access | Times Cited: 117
Small molecules in the treatment of COVID-19
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 78
A Global Picture: Therapeutic Perspectives for COVID-19
Vivek P. Chavda, Carron Kapadia, Shailvi Soni, et al.
Immunotherapy (2022) Vol. 14, Iss. 5, pp. 351-371
Open Access | Times Cited: 71
Oral antiviral treatments for COVID-19: opportunities and challenges
Laila Rahmah, Sunny O. Abarikwu, Amanuel Godana Arero, et al.
Pharmacological Reports (2022) Vol. 74, Iss. 6, pp. 1255-1278
Open Access | Times Cited: 70
Fluorine-a small magic bullet atom in the drug development: perspective to FDA approved and COVID-19 recommended drugs
Girish Chandra, Durg Vijay Singh, Gopal Kumar Mahato, et al.
Chemical Papers (2023) Vol. 77, Iss. 8, pp. 4085-4106
Open Access | Times Cited: 44
Efficacy and Safety of Antimalarial as Repurposing Drug for COVID-19 Following Retraction of Chloroquine and Hydroxychloroquine
Irma Rahayu Latarissa, Miski Aghnia Khairinisa, Ghina Nadhifah Iftinan, et al.
Clinical Pharmacology Advances and Applications (2025) Vol. Volume 17, pp. 1-11
Open Access | Times Cited: 1
A comprehensive review on pyrimidine analogs-versatile scaffold with medicinal and biological potential
N. Jeelan Basha, Naganna M. Goudgaon
Journal of Molecular Structure (2021) Vol. 1246, pp. 131168-131168
Closed Access | Times Cited: 91
First electrochemical evaluation of favipiravir used as an antiviral option in the treatment of COVID-19: A study of its enhanced voltammetric determination in cationic surfactant media using a boron-doped diamond electrode
Shabnam Allahverdiyeva, Oruç Yunusoğlu, Yavuz Yardım, et al.
Analytica Chimica Acta (2021) Vol. 1159, pp. 338418-338418
Open Access | Times Cited: 84
A novel stability-indicating HPLC-DAD method for determination of favipiravir, a potential antiviral drug for COVID-19 treatment; application to degradation kinetic studies and in-vitro dissolution profiling
Hoda M. Marzouk, Mamdouh R. Rezk, Amira S. Gouda, et al.
Microchemical Journal (2021) Vol. 172, pp. 106917-106917
Open Access | Times Cited: 78
Innovative electrochemical sensor for the precise determination of the new antiviral COVID-19 treatment Favipiravir in the presence of coadministered drugs
Mona A. Mohamed, Ghada M. G. Eldin, S. Ismail, et al.
Journal of Electroanalytical Chemistry (2021) Vol. 895, pp. 115422-115422
Open Access | Times Cited: 74
Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update
Claudio Borghi, Justyna Domienik‐Karłowicz, Andrzej Tykarski, et al.
Cardiology Journal (2021) Vol. 28, Iss. 1, pp. 1-14
Open Access | Times Cited: 63
Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates
Liliana Rodrigues, Renata Bento Cunha, Tatiana Vassilevskaia, et al.
Molecules (2022) Vol. 27, Iss. 9, pp. 2723-2723
Open Access | Times Cited: 63
Pharmacological treatment of COVID-19: an opinion paper
Alberto García‐Lledó, Javier Gómez‐Pavón, Juan González del Castillo, et al.
Revista Española de Quimioterapia (2021) Vol. 35, Iss. 2, pp. 115-130
Open Access | Times Cited: 62
Recent review of COVID-19 management: diagnosis, treatment and vaccination
Vivek P. Chavda, Suneetha Vuppu, Toshika Mishra, et al.
Pharmacological Reports (2022) Vol. 74, Iss. 6, pp. 1120-1148
Open Access | Times Cited: 55
Solubility of favipiravir (as an anti-COVID-19) in supercritical carbon dioxide: An experimental analysis and thermodynamic modeling
Seyed Ali Sajadian, Nedasadat Saadati Ardestani, Nadia Esfandiari, et al.
The Journal of Supercritical Fluids (2022) Vol. 183, pp. 105539-105539
Open Access | Times Cited: 48
Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care
Pallav L. Shah, Christopher M. Orton, Beatriz Grinsztejn, et al.
The Lancet Respiratory Medicine (2022) Vol. 11, Iss. 5, pp. 415-424
Open Access | Times Cited: 44
COVID‐19: A systematic review and update on prevention, diagnosis, and treatment
Hooman Aghamirza Moghim Aliabadi, Reza Eivazzadeh‐Keihan, Arezoo Beig Parikhani, et al.
MedComm (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 43
Evolution of Influenza Viruses—Drug Resistance, Treatment Options, and Prospects
Julia M. Smyk, Natalia Szydłowska, Weronika Szulc, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12244-12244
Open Access | Times Cited: 42
Involvement of the Liver in COVID-19: A Systematic Review
Jayani Kariyawasam, Umesh Jayarajah, Visula Abeysuriya, et al.
American Journal of Tropical Medicine and Hygiene (2022) Vol. 106, Iss. 4, pp. 1026-1041
Open Access | Times Cited: 38
Rapid and ecofriendly UPLC quantification of Remdesivir, Favipiravir and Dexamethasone for accurate therapeutic drug monitoring in Covid-19 Patient’s plasma
Aml A. Emam, Eglal A. Abdelaleem, Esraa H. Abdelmomen, et al.
Microchemical Journal (2022) Vol. 179, pp. 107580-107580
Open Access | Times Cited: 38
What are the current anti-COVID-19 drugs? From traditional to smart molecular mechanisms
Sawsan Aboul‐Fotouh, Ahmed N. Mahmoud, Esraa M. Elnahas, et al.
Virology Journal (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 29
Synergistic effect of gold nanoparticles anchored on conductive carbon black as an efficient electrochemical sensor for sensitive detection of anti-COVID-19 drug Favipiravir in absence and presence of co-administered drug Paracetamol
Rasha M.K. Mohamed, Sabrein H. Mohamed, Aml M. Asran, et al.
Microchemical Journal (2023) Vol. 190, pp. 108696-108696
Open Access | Times Cited: 25
Discovery of Natural Bisbenzylisoquinoline Analogs from the Library of Thai Traditional Plants as SARS-CoV-2 3CLPro Inhibitors: In Silico Molecular Docking, Molecular Dynamics, and In Vitro Enzymatic Activity
Nopawit Khamto, Kraikrit Utama, Suriya Tateing, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 7, pp. 2104-2121
Closed Access | Times Cited: 24
Preparing for the next viral threat with broad-spectrum antivirals
Marwah Karim, Chieh‐Wen Lo, Shirit Einav
Journal of Clinical Investigation (2023) Vol. 133, Iss. 11
Open Access | Times Cited: 24
Page 1 - Next Page

Scroll to top